SWOG clinical trial number
CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Open
Phase
II
Abbreviated Title
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse<br />
Status Notes
This study is active in SWOG effective 4/1/21.
Activated
12/04/2020
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Leukemia

Treatment

Blinatumomab Nivolumab

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.